TABLE 2.
Lumbar CSF Levels of APP, sAPPα, sAPPβ, Aβ1-42, NCAM-1, L1CAM, Tau, P-tau, and TP Measured Across the Six Primary Groups and Plasmaa,b
| APP | sAPPα | sAPPβ | Aβ1-42 | NCAM-1 | L1CAM | Tau | P-tau | TP (μg/mL) | |
|---|---|---|---|---|---|---|---|---|---|
| Control | 406.7 ± 290.8 | 136.2 ± 81.7 | 1139 ± 942.7 | 0.792 ± 0.3 | 140.5 ± 68.5 | 74.43 ± 71.7 | 6.09 ± 4.7 | 1.14 ± 0.6 | 1077 ± 435.1 |
| IVH I-II | 313.1 ± 237.3 | 163.1 ± 130.9 | 848.9 ± 460.5 | 0.861 ± 0.5 | 104.9 ± 51.9 | 63.36 ± 33.1 | 3.46 ± 3.1 | 0.99 ± 0.5 | 1365 ± 1098 |
| IVH III-IV | 523.1 ± 278.6 | 377.9 ± 376.5 | 1085 ± 698.6 | 1.274 ± 0.7 | 258.9 ± 129.3 | 76.00 ± 51.1 | 9.55 ± 12.9 | 1.47 ± 0.8 | 1963 ± 952.1 |
| PHH | 1416 ± 806.3 | 1667 ± 1227 | 16 678 ± 36 068 | 0.953 ± 0.7 | 356.4 ± 152.4 | 191.8 ± 93.5 | 20.28 ± 33.9 | 1.98 ± 1.2 | 3748 ± 2403 |
| VEWOH | 330.7 ± 267.9 | 97.4 ± 60.9 | 659.5 ± 760.1 | 0.821 ± 0.7 | 119.4 ± 77.1 | 28.68 ± 22.3 | 5.68 ± 6.4 | 0.71 ± 0.6 | 772.2 ± 371.3 |
| HIE | 371.3 ± 209.5 | 168.9 ± 171.6 | 1002 ± 1605 | 0.335 ± 0.2 | 184.9 ± 72.9 | 24.82 ± 22.0 | 9.20 ± 9.6 | 0.85 ± 0.4 | 1060 ± 448.7 |
| Plasma | 139.87 ± 21.4 | 54.02 ± 31.9 | 21.43 ± 3.2 | 0.555 ± 0.2 | 482.33 ± 63.1 | 15.75 ± 4.1 | 0.242 ± 0.1 | 0.109 ± 0.001 | 49139 ± 6187 |
aAPP, amyloid precursor protein; HIE, hypoxic-ischemic encephalopathy; IVH, intraventricular hemorrhage; L1CAM, L1 cell adhesion molecule; NCAM-1, neural cell adhesion molecule-1; PHH, posthemorrhagic hydrocephalus; sAPPα, soluble amyloid precursor protein α; sAPPβ, soluble amyloid precursor protein β; TP, total protein; VEWOH, ventricular enlargement without hydrocephalus.
bProtein levels are shown as mean ± standard deviation and all are in ng/mL, except TP, which is in μg/mL.